Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 26, Issue 9, 2007, Pages 1495-1498

  Tam, Lai Shan ^a   Tomlinson, Brian ^a   Chu, Tanya T ^a   Li, Tena K ^a   Li, Edmund K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Insulin resistance; Lipid profile; Rheumatoid arthritis; TNF blocker

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; ISONIAZID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISOLONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547631047     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0539-8     Document Type: Article

References (19)

1. Van_Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862-873
2. Sattar N, McCarey DW, Capell H et al (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957-2963
3. Grundy SM, Brewer HB Jr, Cleeman JI et al (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
4. Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765-2775
5. Dessein PH, Joffe BI, Stanwix AE (2002) Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: A pilot study. Arthritis Res 4:R12
6. Feldmann M, Brennan FM, Maini RN (1996). Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14:397-440
7. Cauza E, Cauza K, Hanusch-Enserer U et al (2002) Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114:1004-1007
8. Popa C, Netea MG, Radstake T et al (2005) Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64:303-305
9. Vis M, Nurmohamed MT, Wolbink G et al (2005) Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32:252-255
10. Seriolo B, Paolino S, Sulli A et al (2006) Effects of anti-TNF-{alpha} treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:414-419
11. Kiortsis DN, Mavridis AK, Filippatos TD et al (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:921-923
12. Dahlqvist SR, Engstrand S, Berglin E et al (2006) Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 35:107-111
13. Allanore Y, Kahan A, Sellam J et al (2006) Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365:143-148
14. Kiortsis DN, Mavridis AK, Vasakos S et al (2005) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 64:765-766
15. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83-86
16. Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668
17. Chajek-Shaul T, Friedman G, Stein O et al (1989) Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim Biophys Acta 1001:316-324
18. Tchernof A, Lamarche B, Prud'Homme D et al (1996) The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629-637
19. Jacobsson LT, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of fist cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213-1218